VBI VACCINES INC.

(VBIV)
  Report
Real-time Estimate Cboe BZX  -  12:55 2022-07-05 pm EDT
0.8140 USD   +0.69%
07/01VBI VACCINES INC/BC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
06/28VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022
BU
06/28VBI VACCINES : Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hepatitis B Vaccine Presented at EASL 2022 - Form 8-K
PU
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

VBI VACCINES INC/BC : Submission of Matters to a Vote of Security Holders, Other Events, Financial Statements and Exhibits (form 8-K)

06/23/2022 | 06:03am EDT

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 22, 2022, VBI Vaccines Inc. (the "Company") held its 2022 Annual General Meeting of Shareholders (the "Annual Meeting"). At the Annual Meeting, the shareholders voted to: (1) set the number of directors of the Company at eight (8); (2) elect the nominated directors of the Company to serve until the next annual meeting or until the appointment or election and qualification of their successors; and (3) approve the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm until the next annual meeting of shareholders and authorize the audit committee (the "Audit Committee") of the board of directors of the Company to fix EisnerAmper LLP's remuneration, as set forth in the Company's definitive proxy statement filed with the U.S. Securities and Exchange Commission on April 29, 2022 (the "Proxy Statement"). Each of these proposals is described in more detail in the Proxy Statement.

At the beginning of the Annual Meeting, there were 179,537,122 common shares present at the Annual Meeting in person or by proxy, which represented 69.52% of the outstanding common shares entitled to vote at the Annual Meeting and which constituted a quorum for the transaction of business. Holders of the Company's common shares were entitled to one vote for each share held as of the close of business on April 25, 2022, the record date for the Annual Meeting.

The voting results on these proposals were as follows:

Proposal 1: Set the number of directors of the Company at eight


Votes For    Votes Against   Abstentions   Broker Non-Votes
90,957,682     2,318,677          0           86,045,763



Proposal 2: Election of eight directors


     Director         Votes For     Withheld    Broker Non-Votes
Steven Gillis         76,989,942   16,286,418      86,045,762
Linda Bain            68,460,867   24,815,492      86,045,763

Jeffery R. Baxter 84,987,022 8,289,337 86,045,763 Damian Braga 84,721,290 8,555,070 86,045,762 Joanne Cordeiro 90,821,594 2,454,765 86,045,763 Michel De Wilde 84,830,581 8,445,778 86,045,763 Blaine H. McKee 91,077,164 2,199,195 86,045,763 Christopher McNulty 84,405,251 8,871,108 86,045,763

Each of the eight nominees for director was elected to serve until the next annual meeting of shareholders and until his or her successor has been elected and qualified, or until his or her earlier death, resignation, or removal.

Proposal 3: Approval of the appointment of EisnerAmper LLP as the independent registered public accounting firm of the Company until the next annual meeting of shareholders and authorize the Audit Committee to fix EisnerAmper LLP's remuneration



 Votes For    Votes Against   Abstentions   Broker Non-Votes
175,846,165         0          3,475,956           1










The shareholders approved the appointment of EisnerAmper LLP as the Company's independent registered public accounting firm until the next annual meeting of shareholders and authorized the Audit Committee to fix EisnerAmper LLP's remuneration.

The results reported above are final voting results. No other matters were considered or voted upon at the Annual Meeting.


Item 8.01 Other Events.


On June 22, 2022, the Company issued a press release announcing the voting results from the Annual Meeting. A copy of the press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is hereby incorporated by reference herein.

Item 9.01 Financial Statements and Exhibits.



(d) Exhibits



Exhibit No.   Description

99.1            Press Release dated June 22, 2022
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)

© Edgar Online, source Glimpses

All news about VBI VACCINES INC.
07/01VBI VACCINES INC/BC : Notice of Delisting or Failure to Satisfy a Continued Listing Rule o..
AQ
06/28VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult He..
BU
06/28VBI VACCINES : Announces New Long-Term Follow-Up Clinical Data for its 3-Antigen Adult Hep..
PU
06/28VBI VACCINES INC/BC : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-..
AQ
06/28VBI Vaccines Announces New Long-Term Follow-Up Clinical Data for Its 3-Antigen Adult He..
CI
06/24VBI VACCINES INC.(NASDAQCM : VBIV) dropped from Russell Small Cap Comp Growth Index
CI
06/24VBI VACCINES INC.(NASDAQCM : VBIV) dropped from Russell 2000 Growth Index
CI
06/24VBI VACCINES INC.(NASDAQCM : VBIV) dropped from Russell 3000 Growth Index
CI
06/24VBI VACCINES INC.(NASDAQCM : VBIV) dropped from Russell 3000E Growth Index
CI
06/24VBI VACCINES INC.(NASDAQCM : VBIV) dropped from Russell Microcap Growth Index
CI
More news
Analyst Recommendations on VBI VACCINES INC.
More recommendations
Financials (USD)
Sales 2022 5,77 M - -
Net income 2022 -70,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,99x
Yield 2022 -
Capitalization 209 M 209 M -
Capi. / Sales 2022 36,2x
Capi. / Sales 2023 7,83x
Nbr of Employees 152
Free-Float 79,2%
Chart VBI VACCINES INC.
Duration : Period :
VBI Vaccines Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VBI VACCINES INC.
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 3
Last Close Price 0,81 $
Average target price 6,67 $
Spread / Average Target 725%
EPS Revisions
Managers and Directors
Jeffrey R. Baxter President, Chief Executive Officer & Director
Christopher McNulty CFO, Director & Head-Business Development
Steven H. Gillis Chairman
David Evander Anderson Chief Scientific Officer
Francisco Diaz-Mitoma Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
VBI VACCINES INC.-65.45%209
MODERNA, INC.-40.96%59 644
IQVIA HOLDINGS INC.-23.78%40 704
LONZA GROUP AG-31.09%40 503
SEAGEN INC.16.50%33 154
CELLTRION, INC.-9.34%19 151